Europska Unija - hrvatski - EMA (European Medicines Agency)

taw pharma (ireland) limited - klopidogrel hidroklorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotska sredstva - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

evropa lijek pharma d.o.o. - gefitinib - film tableta - 250 mg/1 tableta - 1 film tableta sadrži: 250 mg gefitiniba

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

pharmascience international limited, lampousas, 1, nicosia, cipar - abirateronacetat - filmom obložena tableta - urbroj: svaka filmom obložena tableta sadrži 500 mg abirateronacetata

Europska Unija - hrvatski - EMA (European Medicines Agency)

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastična sredstva - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase.  chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib.  ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib.  newly diagnosed ph+ all in combination with chemotherapy.

Europska Unija - hrvatski - EMA (European Medicines Agency)

teva b.v. - zoledronske kiseline - osteoporosis; osteitis deformans; osteoporosis, postmenopausal - lijekovi za liječenje bolesti kostiju - treatment of osteoporosis: , in post-menopausal women;, in men; , at increased risk of fracture including those with a recent low-trauma hip fracture. treatment of osteoporosis associated with long-term systemic glucocorticoid therapy: , in post-menopausal women;, in men; , at increased risk of fracture. liječenje pagetova bolest kostiju kod odraslih osoba.

Europska Unija - hrvatski - EMA (European Medicines Agency)

teva b.v. - ribavirin - hepatitis c, kronični - antivirusni lijekovi za sustavnu uporabu - ribavirin teva pharma b. is indicated in combination with other medicinal products for the treatment ofchronic hepatitis c (chc) in adults (see sections 4. 2, 4. 4 i 5. ribavirin teva pharma b. is indicated in combination with other medicinal products for the treatment ofchronic hepatitis c (chc) for paediatric patients (children 3 years of age and older and adolescents) notpreviously treated and without liver decompensation (see sections 4. 2, 4. 4 i 5.

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

glaxosmithkline dungarvan ltd., knockbrack, dungarvan, county waterford, irska - paracetamol fenilefrinklorid gvaifenezin - kapsula, tvrda - 500 mg + 6,1 mg + 100 mg - urbroj: svaka kapsula sadrži 500 mg paracetamola, 6,1 mg fenilefrinklorida (što odgovara 5 mg fenilefrin baze) i 100 mg gvaifenezina

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

glaxosmithkline dungarvan ltd., knockbrack, dungarvan, county waterford, irska - paracetamol fenilefrinklorid gvaifenezin - prašak za oralnu otopinu - 1000 mg + 12,2 mg + 200 mg - urbroj: svaka jednodozna vrećica sadrži 1000 mg paracetamola, 12,2 mg fenilefrinklorida (što odgovara 10 mg fenilefrin baze) i 200 mg gvaifenezina

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

clinres farmacija d.o.o. - askorbinska kiselina, fenilefrin, kofein, paracetamol, terpin - tableta - 500 mg/1 tableta+ 25 mg/1 tableta+ 5 mg/1 tableta+ 20 mg/1 tableta+ 30 mg/1 tableta - 1 tableta sadrži: 500 mg paracetamol + 25 mg kofein + 5 mg fenilefrinhidrohlorid + 20 mg terpinhidrat + 30 mg askorbinska kiselina

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

clinres farmacija d.o.o. - askorbinska kiselina, fenilefrin, paracetamol - prašak za oralni rastvor - 1000 mg/1 kesica+ 40 mg/1 kesica+ 10 mg/1 kesica - 1 kesica sa praškom za oralni rastvor sadrži: 1000 mg paracetamola 40 mg askorbinske kiseline 10 mg fenilefrinhidrohlorida